A large study by researchers at the University of Pittsburgh has uncovered a mechanism that offers novel potential therapeutic opportunities for preventing or treating Type 2 diabetes.
Published today in the journal Cell Reports the study demonstrates the involvement of a small molecule that could be very important for the development of therapies for Type 2 diabetes.
Treatment of diabetes in humans has been somewhat difficult because people have different techniques and procedures to regulate blood sugar and insulin levels said senior author S. James Stearns Ph. D. professor of Cell and Developmental Biology at the University of Pittsburgh. There are different medical applications of medications.
But here we have been able to demonstrate a new and previously undescribed mechanism of action for GLP-1 receptors.
Glucofacts-the protein compound GLP-1 receptors recognize release or activate in plasma. The compound generates voltage-dependent VEGFA receptor (VEGRate) receptors (Molars 2014).
Voltage-dependent receptors (VDRs) are proteins that bind to glucose hormone receptors expressed on the surface of cells. One way to treat Type 2 diabetes is to use insulin: the hormone stimulates VDCA a substance formed from VGRate receptors to control blood sugar in the body slowly for an average of 15-20 minutes.
Scientists translated this to humans.
To elucidate the action of the compound the researchers delved on the GLP-1 receptor interactions locked in the receptors cell membranes.
In previous studies we were able to show that phospholipids are elevated in the presence of the compound said co-first author Allegra Gonzalez Ph. D. of the University of Pittsburgh. In this new study we were able to identify a common pathway between phospholipids and VDRs.